The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms

Jeffrey S. Flier, Mary Jean Moore, Gregory R. Mundy, Kenneth J. Ibbotson, Sharyn M. D'souza, Ellen L. Simpson, John W. Jacobs, T. John Martin

Research output: Contribution to journalReview articlepeer-review

286 Scopus citations


HYPERCALCEMIA is one of the most common metabolic complications of cancer. It has fascinated clinicians since it was first recognized 60 years ago by Zondek et al.1 It is now being recognized more commonly, as is primary hyperparathyroidism, because of the advent of routine measurement of the serum calcium level.2,3 The estimated incidence of the hypercalcemia of cancer is 150 new cases per million persons per year.2,3 This compares with an annual incidence of approximately 250 new cases of primary hyperparathyroidism per year.2,3 However, the relative frequency of cancer as a cause of hypercalcemia is even greater in hospital populations,.

Original languageEnglish (US)
Pages (from-to)1718-1727
Number of pages10
JournalNew England Journal of Medicine
Issue number26
StatePublished - Jun 28 1984
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms'. Together they form a unique fingerprint.

Cite this